Galway

• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended recruitment
  2024-516137-13-00 5 2014-12-18 Metastatic Prostate Cancer
• A clinical research study comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer. Halted
  2024-515237-15-00 10 2025-01-21 Advanced head and neck cancer
• IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]) Ended
  2023-508381-16-00 4 2024-06-13 Post-Traumatic Stress Disorder
• A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended
  2023-507240-37-00 4 2024-04-30 celiac disease
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized … Ended
  2023-504487-41-00 5 2023-11-28 COVID-19
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15 Squamous cell carcinoma of head and neck
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended
  2023-506931-13-00 5 2023-01-30 Overweight and obesity and type 2 diabetes
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended
  2024-514336-24-00 5 2022-03-24 Familial Chylomicronemia Syndrome (FCS)
• Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. … Ended
  2024-516945-37-00 2 2021-11-04 Relapsed/ refractory multiple myeloma
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-P … Ended
  2023-509698-21-00 5 2021-03-17 Prevention of post abdominal surgery incisional infection.
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use … Ended
  2023-503771-13-00 4 2021-01-28 Classic Congenital Adrenal Hyperplasia
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat … Ended
  2024-514808-13-00 5 2015-03-06 Localised prostate cancer at high risk of recurrence

Showing 73–96 of 97 trials